ReviewFrontiers in medicine2026
Neovascular glaucoma: pathophysiology, diagnosis, and contemporary management.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neovascular glaucoma (NVG) is a vision-threatening secondary glaucoma driven by pathologic neovascularization of the iris and anterior chamber angle and is most commonly secondary to ischemic retinal diseases. Despite advances in retinal imaging and anti-vascular endothelial growth factor (anti-VEGF) therapy, NVG remains difficult to manage and is associated with high rates of vision loss, ocular morbidity, and surgical failure. Purpose: This narrative review synthesizes the contemporary understanding of NVG pathophysiology, summarizes diagnostic approaches with emphasis on anterior-segment and retinal imaging, evaluates current medical and surgical management strategies, and highlights emerging directions for research and clinical innovation. Findings: NVG originates from retinal ischemia, which elevates intraocular VEGF and other proangiogenic and inflammatory mediators, inducing rubeosis iridis and fibrovascular membrane formation at the angle. Clinical staging ranges from early iris neovascularization with normal intraocular pressure (IOP) to advanced angle closure with refractory IOP elevation and painful blind eyes. Diagnosis requires careful slit-lamp examination and gonioscopy, supplemented by multimodal imaging: ultrawidefield fluorescein angiography quantifies retinal nonperfusion; and anterior-segment OCT and ultrasound biomicroscopy delineate membrane extent and angle architecture; anterior-segment OCTA is investigational for vascular mapping. Management relies on two parallel goals-rapid suppression of anterior segment neovascularization and definitive treatment of the underlying retinal ischemia. Intravitreal anti-VEGF injections rapidly regress neovascularization and improve surgical conditions, but are temporizing unless combined with panretinal photocoagulation (PRP) or other ischemia-directed therapies. Conclusions and future directions: Long-term success in NVG patients requires integrated, individualized care that couples antiangiogenic bridging, durable management of retinal ischemia, and optimized surgical strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.